Rheumatology Drug Updates on Brentuximab Vedotin, Tofacitinib Citrate

Nineteen patients who developed neutropenia after RTX treatment were retreated with RTX. Of those 19, three developed neutropenia again. No patients developed infections or needed growth factor treatment. In the RA patients who developed LON, no baseline risk factors were identified, except age and female gender. LON in RA occurred, but cases were relatively mild. The authors recommend monitoring blood counts following each cycle of RTX.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Seattle Genetics Inc. News release: Seattle Genetics initiates clinical trial of adcetris (brentuximab vedotin) in systemic lupus erythematosus, a chronic autoimmune disease. 2015 July 9.
2. Pfizer Inc. News Release: Pfizer announces FDA acceptance for review of new drug application for a once-daily formulation of xeljanz (tofacitinib citrate) modified release tablets. 2015 Jul 2.
3. U.S. Food and Drug Administration. Drug safety communication: FDA evaluating the risk of brain deposits with repeated used of gadolinium-based contrast agents for magnetic resonance imaging (MRI). 2015 July 27.
4. U.S. Food and Drug Administration. Safety Alerts for Human Medical Products: Droxia (hydroxyurea). July 2015.
5. Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: Data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1:e000034. doi:10.1136/rmdopen-2014-000034